Neurological Complications in COVID-19 Patients With ECMO Support: A Systematic Review and Meta-Analysis
File version
Author(s)
Jami, Meghana
Premraj, Lavienraj
Etchill, Eric W
Giuliano, Katherine
Bush, Errol L
Kim, Bo Soo
Seal, Stella
Whitman, Glenn
Cho, Sung-Min
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
Size
File type(s)
Location
License
Abstract
Background: Patients with Coronavirus disease 2019 (COVID-19)-related acute respiratory disease (ARDS) increasingly receive extracorporeal membrane oxygenation (ECMO) support. While ECMO has been shown to increase risk of stroke, few studies have examined this association in COVID-19 patients. Objective: We conducted a systematic review to characterise neurological events during ECMO support in COVID-19 patients. Design: Systematic review of cohort and large case series of COVID-19 patients who received ECMO support. Data Sources: Studies retrieved from PubMed, EMBASE, Cochrane, Cochrane COVID-19 Study Register, Web of Science, Scopus, Clinicaltrials.gov, and medRχiv from inception to November 11, 2020. Eligibility Criteria: Inclusion criteria were a) Adult population (>18 year old); b) Positive PCR test for SARS-CoV-2 with active COVID-19 disease; c) ECMO therapy due to COVID-19 ARDS; and d) Neurological events and outcome described while on ECMO support. We excluded articles when no details of neurologic events were available. Results: 1,322 patients from 12 case series and retrospective cohort studies were included in our study. The median age was 49.2, and 75% (n=985) of the patients were male. Diabetes mellitus and dyslipidaemia were the most common comorbidities (24% and 20%, respectively). Most (95%, n=1,241) patients were on venovenous ECMO with a median P:F ratio at the time of ECMO cannulation of 69.1. The prevalence of intracranial haemorrhage (ICH), ischaemic stroke, and hypoxic ischaemic brain injury (HIBI) was 5.9% (n=78), 1.1% (n=15), and 0.3% (n=4), respectively. The overall mortality of the 1,296 ECMO patients in the 10 studies that reported death was 36% (n=477), and the mortality of the subset of patients who had a neurological event was 92%. Conclusions: Neurological injury is a concern for COVID-19 patients who receive ECMO. Further research is required to explore how neuromonitoring protocols can inform tailored anticoagulation management and improve survival in COVID-19 patients with ECMO support.
Journal Title
Heart, Lung and Circulation
Conference Title
Book Title
Edition
Volume
31
Issue
2
Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
Item Access Status
Note
Access the data
Related item(s)
Subject
Cardiovascular medicine and haematology
Neurology and neuromuscular diseases
Science & Technology
Life Sciences & Biomedicine
Cardiac & Cardiovascular Systems
Cardiovascular System & Cardiology
ECMO
Persistent link to this record
Citation
V. Kannapadi, N; Jami, M; Premraj, L; Etchill, EW; Giuliano, K; Bush, EL; Kim, BS; Seal, S; Whitman, G; Cho, S-M, Neurological Complications in COVID-19 Patients With ECMO Support: A Systematic Review and Meta-Analysis, Heart, Lung and Circulation, 2022, 31 (2), pp. 292-298